Abstract

Cancer heterogeneity constitutes the major source of disease progression and therapy failure. Tumors comprise functionally diverse subpopulations, with cancer stem cells (CSCs) as the source of this heterogeneity. Since these cells bear in vivo tumorigenicity and metastatic potential, survive chemotherapy and drive relapse, its elimination may be the only way to achieve long-term survival in patients. Thanks to the great advances in the field over the last few years, we know now that cellular metabolism and stemness are highly intertwined in normal development and cancer. Indeed, CSCs show distinct metabolic features as compared with their more differentiated progenies, though their dominant metabolic phenotype varies across tumor entities, patients and even subclones within a tumor. Following initial works focused on glucose metabolism, current studies have unveiled particularities of CSC metabolism in terms of redox state, lipid metabolism and use of alternative fuels, such as amino acids or ketone bodies. In this review, we describe the different metabolic phenotypes attributed to CSCs with special focus on metabolism-based therapeutic strategies tested in preclinical and clinical settings.

Highlights

  • CANCER (STEM) CELL METABOLISMCancer is a highly heterogeneous disease, in terms of variability among patients, and within a single tumor

  • As opposed to what we summarized in the previous section, recent literature described oxidative phosphorylation (OxPhos) as the main source of energy in cancer stem cells (CSCs) from a number of cancer types (Table 2)

  • Technical advances have allowed the determination of the great metabolic heterogeneity, among individuals suffering from one type of cancer, but within a single tumor

Read more

Summary

INTRODUCTION

Cancer is a highly heterogeneous disease, in terms of variability among patients, and within a single tumor. As opposed to what we summarized, recent literature described OxPhos as the main source of energy in CSCs from a number of cancer types (Table 2) This has been convincingly shown for ROSlow quiescent CD34+ leukemia CSCs (Lagadinou et al, 2013), lung spheroids and CD133+ PDAC cells (Ye et al, 2011; Sancho et al, 2015), as well as CSCs-enriched spheroids form ovarian, cervical and papillary thyroid carcinoma that displayed a reprogrammed metabolism through TCA cycle (Sato et al, 2016; Caria et al, 2018). Since mitochondrial metabolism coupled to OxPhos constitutes a much more efficient

Methods
Findings
CONCLUDING REMARKS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call